Keytruda First Cancer Drug Approved for Any Solid Tumor Based on a Biomarker Instead of Tumor Site

Web Exclusives - FDA Approvals, News & Updates, Web Exclusive

On May 23, 2017, the FDA granted accelerated approval to pembrolizumab (Keytruda; Merck) for the treatment of metastatic, microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors that have progressed after previous treatment and have no appropriate alternative treatments, or for colorectal cancer that has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This is the first time the FDA approved a cancer drug for use in any solid tumor with a specific genetic feature.

“This is an important first for the cancer community. Until now, the FDA has approved cancer treatments based on where in the body the cancer started—for example, lung or breast cancers. We have now approved a drug based on a tumor’s biomarker without regard to the tumor’s original location,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The FDA approval of pembrolizu­mab for this indication was based on data from patients with MSI-H or dMMR solid tumors who participated in 1 of 5 uncontrolled, open-label, multicohort, multicenter, single-arm clinical trials. The overall response rate was 39.6%, and 78% of patients who responded to pembrolizumab had a duration of response lasting ≥6 months. The median duration of response had not been reached at the time of the analysis.

Pembrolizumab can cause serious immune-mediated adverse events, including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. Complications or death related to allogeneic hematopoietic stem-cell transplantation has occurred after therapy with pembrolizumab.

Related Items
Bavencio (Avelumab) Approved for Metastatic Merkel-Cell Carcinoma and for Urothelial Carcinoma
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 24, 2018 in FDA Approvals, News & Updates
Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 24, 2018 in FDA Approvals, News & Updates
Gocovri (Amantadine) First Drug Approved for Dyskinesia in Patients with Parkinson’s Disease
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 24, 2018 in FDA Approvals, News & Updates
Idhifa (Enasidenib), First-in-Class IDH2 Inhibitor, Approved for Relapsed Acute Myeloid Leukemia with IDH2 Mutation
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 24, 2018 in FDA Approvals, News & Updates
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 24, 2018 in FDA Approvals, News & Updates
Last modified: August 10, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME